Respiratory syncytial virus (RSV) is the leading viral pathogen responsible for bronchiolitis and pneumonia in infants. We assessed palivizumab prophylaxis compliance for infants in Puerto Rico. We retrospectively studied data from 868 infants (409 females, 459 males) during the 2009–2010 RSV season. The infants had a mean gestational age of 33 weeks (range 23–41) and a mean birth weight of 1,767 g (range 509–4,120). Only 74 % of the infants with indications received prophylaxis. The main reasons for noncompliance were non-approval by the medical insurance (53 %), parents’ unavailability (31 %), and infant sickness (11 %). Infants with the government medical insurance were more likely to be denied prophylaxis and to receive fewer doses. Parents need to be educated on the importance of RSV prophylaxis. Physicians should be aware that many infants are not being dosed appropriately and that strategies need to be established to improve compliance.
Meissner, H. C., Long, S. S., & American Academy of Pediatrics Committee on Infectious Diseases and Committee on Fetus and Newborn. (2003). Revised indications for the use of palivizumab and respiratory syncytial virus immune globulin intravenous for the prevention of respiratory syncytial virus infections. Pediatrics, 112(6 Pt 1), 1447–1452. PubMedCrossRef
The IMpact-RSV Study Group. (1998). Palivizumab, a humanized respiratory syncytial virus monoclonal antibody, reduces hospitalization from respiratory syncytial virus infection in high-risk infants. Pediatrics, 102, 531–537. CrossRef
American Academy of Pediatrics. (2009). Respiratory syncytial virus. In L. K. Pickering, C. J. Baker, S. S. Long, & D. Kimberlin (Eds.), Red book. 2009 Report of the committee on infectious diseases (28th ed., pp. 560–569). Elk Grove Village: American Academy of Pediatrics.
Diehl, J. L., Daw, J. R., Coley, K. C., & Rayburg, R. (2010). Medical utilization associated with palivizumab compliance in a commercial and managed medicaid health plan. Journal of Managed Care Pharmacy, 16(1), 23–31. PubMed
Roberts, J. R., Martines, J., White, S., et al. (2006). Improving compliance for respiratory syncytial virus prophylaxis [abstract 279]. Poster presented at: Southern regional meeting of the American federation for medical research; March 3–5, 2006; Atlanta, GA.
Langkamp, D. L., Hlavin, S. M., & Bowen, M. (2001). Compliance with palivizumab. Pediatrics Research, 49(4 Pt 2):238A. Poster presented at: American Pediatric Society/Society for Pediatric Research/Ambulatory Pediatric Association Annual Meeting; April 27–May 1, 2001; Baltimore, MD.
Berger, J., Fensterheim, L., O’Rourke, J., et al. (2003). The importance of Synagis compliance in preventing hospitalizations. Pediatric Research, 53(4 Pt 2), 468A–469A.
Frogel, M. P., Stewart, D. L., Hoopes, M., Fernandes, A. W., & Mahadevia, P. J. (2010). A systematic review of compliance with palivizumab administration for RSV immunoprophylaxis. Journal of Management Care Pharmacy, 16(1), 46–58.
Suchanek, D. (2005). The rise and role of specialty pharmacy. Biotechnology Healthcare. Alliance for Health Reform. http://www.allhealth.org/BriefingMaterials/BiotechHealthcareSpecialtyPharmacies-416.pdf. Accessed December 5, 2009.
Study Finds Children More Likely to Receive Recommended RSV Medication Doses When Administered Through Specialty Pharmacy. (2011). 20th of October 2011 @ 06:16 | Source: PR Newswire via BioPortfolio.
- Palivizumab Compliance by Infants in Puerto Rico During the 2009–2010 Respiratory Syncytial Virus Season
- Springer US